INKT
MiNK Therapeutics, Inc.
Key Financials
Operating Income
$-12642136
↓ 12.0%
EPS (Diluted)
$-2.93
↓ 2.4%
Total Assets
$14.2M
↑ 148.9%
Net Income
$-12494260
↓ 15.9%
Cash & Equivalents
$13.4M
↑ 191.9%
Shareholders' Equity
$-14227659.00
↑ 27.4%
Operating Cash Flow
$-5925168.00
↑ 38.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/23/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
| 8-K | 5/15/2026 | View on SEC |
| ARS | 4/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INKT |
| Company Name | MiNK Therapeutics, Inc. |
| CIK | 1840229 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 212-994-8250 |